C0032521||Polymeric
C0027651||Tumor
C0920677||Targeted Delivery
C3179230||Antiangiogenic
C0017337||Gene
C0028606||Nucleic acid-based
C0087111||therapy
C0012634||diseases
C0033684||protein
C0920677||synthetic delivery systems
C0012854||DNA-based
C0087111||therapy
C3178923||chemistry-based strategies
C0920677||gene delivery formulations
C0184511||improved
C0012854||DNA
C1511131||enzymatic
C0314674||degradation
C0014406||milieu
C1753315||prolonged retention
C0032136||plasmid DNA
C0032136||plasmid DNA
C0007447||cationic
C0032426||poly(lysine)
C0032521||polyplex
C0205102||interior
C0032136||plasmid DNA
C0030012||redox
C0012771||disulfide
C0032521||polyplex
C1148560||exchange reaction
C0022023||charged components
C0032136||plasmid DNA
C0071490||poly(N-isopropylacrylamide)
C0005479||biocompatible
C0032483||poly(ethylene glycol)
C0032483||poly(ethylene glycol)
C1705920||species
C0597094||nuclease
C0032136||plasmid DNA
C0220825||investigations
C0005767||blood
C0268000||retention
C0025663||method
C0087111||therapy
C1685100||ligand cyclic (Arg-Gly-Asp) peptide
C0032483||poly(ethylene glycol)
C0027651||tumor
C0017262||gene expression
C3179230||antiangiogenic
C0017337||gene
C0597032||tumor cells
C0015264||exerting
C3179230||antiangiogenesis
C0027651||tumors
C0920677||gene delivery system
C0012634||diseases